Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing GP2, an immunotherapy candidate for preventing breast cancer recurrence. The company has not yet generated revenue and is still in the research, clinical development, and financing phase, with operations centered on advancing its pipeline toward regulatory approval and eventual commercialization.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of GP2, a therapeutic candidate intended to reduce breast cancer recurrence.
Designing and running clinical trials needed to generate safety and efficacy data.
Activities to support future approval, manufacturing scale-up, and launch readiness.
Asiakkaat
The company does not yet have commercial customers because it has not generated revenue or launched a product. Its near-term stakeholders are clinical investigators, trial sites, regulators, and future oncology patients and physicians if GP2 is approved. Longer term, demand would come from breast cancer treatment providers and patients seeking recurrence-prevention therapy.
Hospitals, investigators, and trial participants involved in testing GP2 and generating clinical data.
FDA and other regulators that review trial results and determine whether the product can be approved.
Breast cancer specialists and patients who would use GP2 if it reaches commercialization.
Strategia
The company’s strategy is to advance GP2 through clinical development, secure regulatory approval, and build the infrastructure needed for commercialization. Near term, it must preserve liquidity through equity and/or debt financing while funding trials and related operating costs. Success depends on translating clinical data into a viable breast cancer recurrence-prevention product.
Clinical data is the core value driver and determines whether the program can progress toward approval.
The company has no revenue and must fund operations through external financing.
If development succeeds, the company will need manufacturing, marketing, sales, and distribution capabilities.
Maantiede
The company is headquartered in the United States and its reported activity is centered there. No country-level revenue disclosure is available because Greenwich LifeSciences remains pre-revenue, so geographic exposure is mainly tied to where clinical development, financing, and future commercialization occur. As a U.S. issuer, it is also exposed to U.S. regulatory and capital-market conditions.
Riskit
Greenwich LifeSciences is exposed to the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the need for repeated financing before any product revenue exists. Its reported going-concern status and reliance on equity, debt, and related-party funding make liquidity a central risk, while stock-based compensation and clinical spending can drive large operating losses. Because the company is still pre-commercial, any setback in development or capital markets could materially affect its ability to continue operations.
If GP2 does not demonstrate sufficient safety or efficacy, the program may not advance to approval.
Kohdistuu: Pipeline value and future commercialization
The company has no revenue and expects to continue incurring losses, so it must raise capital to fund operations.
Even positive clinical data may not translate into timely approval or favorable labeling.
Kohdistuu: Time to market and commercialization prospects
Clinical and public-company costs are expected to rise as development progresses.
Kirjanpito
Harkinnanvaraiset erätThe company states its financial statements are prepared assuming continued operations despite recurring losses.
Vaikutus: Affects investor assessment of survival risk and financing needs
Options grants to employees, management, and directors drove expense increases in 2025.
Vaikutus: Raises reported R&D and G&A expenses without cash outflow
Clinical development costs and other obligations require judgment and can change period results.
Vaikutus: Can materially affect quarterly operating losses
ATM offerings and related-party loans are key liquidity sources for a pre-revenue company.
Vaikutus: Affects cash flow, dilution, and balance sheet presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Genprex, Inc.
GNPX · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Greenland Mines Ltd
GRMLW · Biological Products, (No Diagnostic Substances)
Greenland Mines Ltd is a U.S.-based development-stage life sciences company that has not yet generated operating revenue.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Päivitetty: 24.9.2026